Calithera Biosciences, Inc. (NASDAQ:CALA) was the target of a large increase in short interest during the month of April. As of April 15th, there was short interest totalling 2,250,000 shares, an increase of 24.3% from the March 31st total of 1,810,000 shares. Based on an average trading volume of 1,070,000 shares, the days-to-cover ratio is presently 2.1 days.

CALA has been the topic of a number of research reports. SVB Leerink downgraded Calithera Biosciences from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $7.00 to $2.00 in a research note on Tuesday, January 5th. Smith Barney Citigroup reduced their price objective on Calithera Biosciences from $10.00 to $5.00 in a research note on Tuesday, January 5th. Zacks Investment Research downgraded Calithera Biosciences from a “hold” rating to a “sell” rating in a research note on Monday, January 4th. HC Wainwright reduced their price objective on Calithera Biosciences from $9.50 to $4.00 and set a “buy” rating on the stock in a research note on Tuesday, January 5th. Finally, Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell cut their target price on Calithera Biosciences from $10.00 to $5.00 in a research report on Tuesday, January 5th. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $5.04.

A number of institutional investors have recently made changes to their positions in the business. JPMorgan Chase & Co. grew its position in Calithera Biosciences by 10.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 24,517 shares of the biotechnology company’s stock valued at $84,000 after acquiring an additional 2,395 shares during the last quarter. Grimes & Company Inc. grew its position in Calithera Biosciences by 13.2% in the 4th quarter. Grimes & Company Inc. now owns 39,974 shares of the biotechnology company’s stock valued at $196,000 after acquiring an additional 4,674 shares during the last quarter. Rhumbline Advisers grew its position in Calithera Biosciences by 8.1% in the 4th quarter. Rhumbline Advisers now owns 73,765 shares of the biotechnology company’s stock valued at $362,000 after acquiring an additional 5,530 shares during the last quarter. Principal Financial Group Inc. grew its position in Calithera Biosciences by 71.1% in the 4th quarter. Principal Financial Group Inc. now owns 17,606 shares of the biotechnology company’s stock valued at $86,000 after acquiring an additional 7,319 shares during the last quarter. Finally, Hsbc Holdings PLC bought a new position in Calithera Biosciences in the 4th quarter valued at $50,000. 73.99% of the stock is currently owned by institutional investors.

Shares of NASDAQ CALA traded down $0.08 during trading hours on Tuesday, hitting $2.11. 17,251 shares of the company traded hands, compared to its average volume of 1,471,372. The stock has a market capitalization of $156.24 million, a price-to-earnings ratio of -1.59 and a beta of 1.77. The company’s 50 day moving average price is $2.41 and its 200 day moving average price is $3.47. Calithera Biosciences has a 12 month low of $2.03 and a 12 month high of $7.42.

Calithera Biosciences (NASDAQ:CALA) last released its earnings results on Monday, March 15th. The biotechnology company reported ($0.32) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.32). Sell-side analysts forecast that Calithera Biosciences will post -1.31 EPS for the current fiscal year.

Calithera Biosciences Company Profile

Calithera Biosciences, Inc, a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors.

Featured Story: Hedge Funds – Risk or Reward?

Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.